[HTML][HTML] Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
W Külper-Schiek, V Piechotta, A Pilic, M Batke… - Frontiers in …, 2022 - frontiersin.org
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is currently the dominant variant globally. This third interim analysis of a living …
variant is currently the dominant variant globally. This third interim analysis of a living …
[PDF][PDF] Facing the Omicron variant–How well do vaccines protect against mild and severe 1 COVID-19? Third interim analysis of a living systematic review 2
S Dreveton, B Geurts, J Koch, S Köppe, M Treskova… - academia.edu
We systematically searched the COVID-19 literature for controlled studies evaluating the 18
effectiveness of COVID-19 vaccines approved in the European Union up to 14/01/2022, 19 …
effectiveness of COVID-19 vaccines approved in the European Union up to 14/01/2022, 19 …
[HTML][HTML] Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
W Külper-Schiek, V Piechotta, A Pilic… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is currently the dominant variant globally. This third interim analysis of a living …
variant is currently the dominant variant globally. This third interim analysis of a living …
[PDF][PDF] Facing the Omicron variant–How well do vaccines protect against mild and severe 1 COVID-19? Third interim analysis of a living systematic review 2
S Dreveton, B Geurts, J Koch, S Köppe, M Treskova… - scholar.archive.org
We systematically searched the COVID-19 literature for controlled studies evaluating the 18
effectiveness of COVID-19 vaccines approved in the European Union up to 14/01/2022, 19 …
effectiveness of COVID-19 vaccines approved in the European Union up to 14/01/2022, 19 …
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
W Külper-Schiek, V Piechotta, A Pilic… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is currently the dominant variant globally. This third interim analysis of a living …
variant is currently the dominant variant globally. This third interim analysis of a living …
Facing the omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
W Külper-Schiek, V Piechotta, A Pilic, M Batke… - 2022 - cabidigitallibrary.org
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is currently the dominant variant globally. This third interim analysis of a living …
variant is currently the dominant variant globally. This third interim analysis of a living …
Facing the Omicron variant–How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
W Külper-Schiek, V Piechotta, A Pilic, M Batke… - medRxiv, 2022 - medrxiv.org
Abstract Background The SARS-CoV-2 Omicron variant is currently the dominant variant
globally. This 3rd interim analysis of a living systematic review summarizes evidence on …
globally. This 3rd interim analysis of a living systematic review summarizes evidence on …
[PDF][PDF] Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
W Külper-Schiek, V Piechotta, A Pilic, M Batke… - 2022 - scienceopen.com
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is currently the dominant variant globally. This third interim analysis of a living …
variant is currently the dominant variant globally. This third interim analysis of a living …
[HTML][HTML] Facing the Omicron variant–How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review
W Külper-Schiek, V Piechotta, A Pilic, M Batke… - 2022 - europepmc.org
Background The SARS-CoV-2 Omicron variant is currently the dominant variant globally.
This 3 rd interim analysis of a living systematic review summarizes evidence on COVID-19 …
This 3 rd interim analysis of a living systematic review summarizes evidence on COVID-19 …
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
W Külper-Schiek, V Piechotta, A Pilic… - Frontiers in …, 2022 - europepmc.org
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is currently the dominant variant globally. This third interim analysis of a living …
variant is currently the dominant variant globally. This third interim analysis of a living …